- Combination of donafenib and anti-PD-1 antibody plus trans-arterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (uHCC).Gu, Shanzhi; Tan, Yulin; Zhou, Huan; Hu, Hongtao; Zheng, Tongsen; Zheng, Zhendong; Zhu, Xu; Yuan, MuAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 3
- Donafenib combined with anti-PD-1 antibodies plus transarterial therapy for initially unresectable hepatocellular carcinomaWen, Yaohong; Fu, Shunjun; He, Guolin; Cai, Lei; Liu, Yahong; Li, Xinmin; Xu, Yuyan; Wang, Chunming; Zhong, Kaihang; Zhang, Cheng; Xie, Qingyu; Pan, MingxinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis.Dong, Wei; Zhang, Songyan; Huo, Zhuoni; Lu, Junrong; Liu, Haishi; Wang, Ping; Zhang, YubaoAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Chemoembolization plus hepatic arterial infusion chemotherapy combined with donafenib, anti-PD-1 antibody for unresectable hepatocellular carcinoma (uHCC): A retrospective analysis.
11阅读
